Immunic (NASDAQ:IMUX) & Sensei Biotherapeutics (NASDAQ:SNSE) Critical Analysis

Immunic (NASDAQ:IMUX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Immunic and Sensei Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0	0	2	0	3.00
Sensei Biotherapeutics	0	0	3	0	3.00

Immunic currently has a consensus target price of $8.50, indicating a potential upside of 658.93%. Sensei Biotherapeutics has a consensus target price of $4.33, indicating a potential upside of 628.29%. Given Immunic’s higher probable upside, equities analysts plainly believe Immunic is more favorable than Sensei Biotherapeutics.

Profitability

This table compares Immunic and Sensei Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-161.82%	-118.57%
Sensei Biotherapeutics	N/A	-46.67%	-40.88%

Valuation & Earnings

This table compares Immunic and Sensei Biotherapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61 million	($1.83)	-0.61
Sensei Biotherapeutics	N/A	N/A	-$34.10 million	($1.21)	-0.49

Immunic is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Immunic has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.

Insider and Institutional Ownership

51.8% of Immunic shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 25.5% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Immunic on 6 of the 9 factors compared between the two stocks.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.